ES3015717T3 - A lysyl oxidase-like 2 inhibitor for use in treating myelofibrosis - Google Patents

A lysyl oxidase-like 2 inhibitor for use in treating myelofibrosis Download PDF

Info

Publication number
ES3015717T3
ES3015717T3 ES17849478T ES17849478T ES3015717T3 ES 3015717 T3 ES3015717 T3 ES 3015717T3 ES 17849478 T ES17849478 T ES 17849478T ES 17849478 T ES17849478 T ES 17849478T ES 3015717 T3 ES3015717 T3 ES 3015717T3
Authority
ES
Spain
Prior art keywords
compound
acid
loxl2
day
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17849478T
Other languages
English (en)
Spanish (es)
Inventor
Gretchen Bain
Jillian Frances Evans
Deidre A Mackenna
John Howard Hutchinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmakea Inc
Original Assignee
Pharmakea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmakea Inc filed Critical Pharmakea Inc
Application granted granted Critical
Publication of ES3015717T3 publication Critical patent/ES3015717T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
ES17849478T 2016-09-07 2017-09-06 A lysyl oxidase-like 2 inhibitor for use in treating myelofibrosis Active ES3015717T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662384542P 2016-09-07 2016-09-07
US201762509460P 2017-05-22 2017-05-22
PCT/US2017/050331 WO2018048942A1 (en) 2016-09-07 2017-09-06 Uses of a lysyl oxidase-like 2 inhibitor

Publications (1)

Publication Number Publication Date
ES3015717T3 true ES3015717T3 (en) 2025-05-07

Family

ID=61561650

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17849478T Active ES3015717T3 (en) 2016-09-07 2017-09-06 A lysyl oxidase-like 2 inhibitor for use in treating myelofibrosis

Country Status (13)

Country Link
US (3) US11793797B2 (enExample)
EP (3) EP3509594B1 (enExample)
JP (1) JP7097874B2 (enExample)
KR (2) KR102615565B1 (enExample)
CN (2) CN117180280A (enExample)
AU (1) AU2017324444A1 (enExample)
BR (1) BR112019004513A2 (enExample)
CA (1) CA3036062A1 (enExample)
ES (1) ES3015717T3 (enExample)
IL (1) IL265232A (enExample)
MA (1) MA46203A (enExample)
MX (1) MX2019002612A (enExample)
WO (1) WO2018048942A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016144702A1 (en) * 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
WO2016144703A1 (en) 2015-03-06 2016-09-15 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
CN108884049A (zh) 2016-02-09 2018-11-23 法玛克亚公司 喹啉酮赖氨酰氧化酶样2抑制剂及其用途
MX390964B (es) 2016-09-07 2025-03-21 Pharmakea Inc Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion.
MX2019002612A (es) 2016-09-07 2019-08-21 Pharmakea Inc Usos de un inhibidor de lisil-oxidasa tipo 2.
US20210002641A1 (en) * 2018-03-16 2021-01-07 The Regents Of The University Of Michigan Compositions and methods for treating graves disease
CN112441916A (zh) * 2019-08-29 2021-03-05 广东药科大学 新型苯乙酸衍生物、其制备方法及其作为药物的用途
JP2022548725A (ja) * 2019-09-20 2022-11-21 レネオ ファーマシューティカルズ，インク． 腎臓病の治療におけるｐｐａｒデルタアゴニストの使用
WO2021086973A2 (en) * 2019-10-28 2021-05-06 University Of Iowa Research Foundation Formulation for delivery of lubricin gene
CN110714016B (zh) * 2019-11-29 2021-08-20 长沙学院 Jnk基因及其作为鱼类细菌性肠炎诊断分子标记物和治疗靶点的应用
CN112662763A (zh) * 2020-03-10 2021-04-16 博尔诚（北京）科技有限公司 一种检测常见两性癌症的探针组合物
CN116600802A (zh) * 2020-12-03 2023-08-15 德尔塔4有限公司 沙罗格列扎和肉豆蔻酸用于治疗局灶性节段性肾小球硬化(fsgs)
CN117731665B (zh) * 2021-07-12 2026-03-27 兰州大学 喹吖因或其药学上可接受的盐在制备治疗非酒精性脂肪肝药物中的应用
US20250249013A1 (en) * 2022-04-08 2025-08-07 The Regents Of The University Of California Combination metabolic-epigenetic treatment for early lung cancer

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
IE56702B1 (en) 1982-12-01 1991-11-06 Usv Pharma Corp Antiinflammatory antiallergic compounds
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5021456A (en) 1988-02-25 1991-06-04 Merrell Dow Pharmaceuticals Inc. Inhibitors of lysyl oxidase
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5250532A (en) 1991-04-11 1993-10-05 Dowelanco 3,4,N-trisubstituted-4,5-dihydro-1H-pyrazole-1-carboxamides and their use as insecticides
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US5691364A (en) 1995-03-10 1997-11-25 Berlex Laboratories, Inc. Benzamidine derivatives and their use as anti-coagulants
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US6632823B1 (en) 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
MXPA02007047A (es) 2000-01-18 2002-12-13 Pfizer Prod Inc Antagonista del factor liberador de corticotropina.
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US20030134836A1 (en) 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
US20020147198A1 (en) 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
FI20030030A0 (fi) 2003-01-09 2003-01-09 Orion Corp Uusia yhdisteitä
CN1787817B (zh) 2003-05-19 2011-09-07 Irm责任有限公司 免疫抑制剂化合物及组合物
WO2005082370A1 (en) 2004-01-29 2005-09-09 Pfizer Products Inc. Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders
CA2558568A1 (en) 2004-03-12 2005-09-29 Eli Lilly And Company Opioid receptor antagonists
WO2005092836A1 (en) 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
CN1976907A (zh) 2004-04-30 2007-06-06 武田药品工业株式会社 杂环酰胺化合物及其作为mmp－13抑制剂的用途
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
BRPI0515143A (pt) 2004-09-10 2008-07-08 Pfizer Prod Inc usos de derivados azabicìclicos de piridiloximetila e benzisoxazol para a preparação de uma composição farmacêutica para o tratamento dos distúrbios de humor
JP2008512441A (ja) 2004-09-10 2008-04-24 ファイザー・プロダクツ・インク ピリジルオキシメチル、及びベンズイソオキサゾール・アザビシクロ誘導体を使用する、認知障害の治療方法
WO2006052546A2 (en) 2004-11-04 2006-05-18 Neurogen Corporation Pyrazolylmethyl heteroaryl derivatives
DE102004056226A1 (de) 2004-11-22 2006-05-24 Burchardt, Elmar Reinhold, Dr.Dr. Neuartige Inhibitoren der Lysyloxidase
US7759493B2 (en) 2005-01-31 2010-07-20 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
AR055041A1 (es) 2005-03-23 2007-08-01 Merck Frosst Canada Ltd Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas.
CA2618586A1 (en) 2005-08-11 2007-02-15 Merck Frosst Canada Ltd. Novel substituted 1,2,3-triazolylmethyl-benzothiophene or -indole and their use as leukotriene biosynthesis inhibitors
US7405302B2 (en) 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
ITMI20051943A1 (it) 2005-10-14 2007-04-15 Procos Spa Processo di risoluzione anantiomerica di 2-aminometil-pirrolidine 1-sostitute per ammidazione in presenza di lipasi
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US20070225285A1 (en) 2005-11-04 2007-09-27 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
US20070219206A1 (en) 2005-11-04 2007-09-20 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (flap) inhibitors
WO2007087250A2 (en) 2006-01-23 2007-08-02 Amira Pharmaceuticals, Inc. Tricyclic inhibitors of 5-lipoxygenase
GB0614579D0 (en) 2006-07-21 2006-08-30 Black James Foundation Pyrimidine derivatives
EP2121703A4 (en) 2006-08-18 2011-12-28 Astrazeneca Ab THIENOPYRIMIDIN-4-ON- AND THIENOPYRIDAZIN-7-ONDERIVATES AS MCH-RL ANTAGONISTS
US20100074897A1 (en) * 2006-12-01 2010-03-25 University Of Utah Research Foundation Methods and Compositions related to HIF-1 alpha
IL184627A0 (en) 2007-07-15 2008-12-29 Technion Res & Dev Foundation Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue
ES2700141T3 (es) 2007-08-02 2019-02-14 Gilead Biologics Inc Anticuerpos inhibidores LOXL2 y usos de los mismos
KR20130031233A (ko) 2009-07-28 2013-03-28 아나코르 파마슈티칼스 인코포레이티드 삼치환된 붕소 함유 분자
EP2467162A4 (en) * 2009-08-21 2013-10-02 Gilead Biologics Inc THERAPEUTIC PROCESSES AND RELATED COMPOSITIONS
US8680246B2 (en) * 2010-02-04 2014-03-25 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (LOXL2)
JP2013518909A (ja) 2010-02-08 2013-05-23 キナゲン，インク． アロステリックキナーゼ阻害が関係する治療方法および組成物
US8513230B2 (en) 2010-03-05 2013-08-20 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
RU2014120166A (ru) 2011-10-20 2015-11-27 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина
BR112014026399B1 (pt) 2012-04-25 2022-11-01 Raqualia Pharma Inc Composto de fórmula (ii), composição farmacêutica, uso e processo para preparar uma composição farmacêutica
JP2016500700A (ja) * 2012-10-30 2016-01-14 ギリアード サイエンシーズ， インコーポレイテッド リシルオキシダーゼ様２（ｌｏｘｌ２）に関する治療および診断方法
CN104854086B (zh) 2012-12-18 2017-06-27 Ea制药株式会社 杂环酰胺衍生物和含有其的药物
JP2018522812A (ja) 2014-08-05 2018-08-16 ザ ユニヴァーシティ オブ ブリティッシュ コロンビア カスパーゼ−６のモジュレーター
US9051320B1 (en) * 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
WO2016128529A1 (en) 2015-02-15 2016-08-18 F. Hoffmann-La Roche Ag 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists
WO2016144703A1 (en) * 2015-03-06 2016-09-15 Pharmakea, Inc. Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
WO2016144702A1 (en) 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
MX390964B (es) 2016-09-07 2025-03-21 Pharmakea Inc Formas cristalinas de un inhibidor tipo lisil oxidasa 2 y metodos de realizacion.
MX2019002612A (es) 2016-09-07 2019-08-21 Pharmakea Inc Usos de un inhibidor de lisil-oxidasa tipo 2.

Also Published As

Publication number Publication date
US20240415824A1 (en) 2024-12-19
US20210177820A1 (en) 2021-06-17
EP3509594B1 (en) 2025-02-26
US11793797B2 (en) 2023-10-24
JP7097874B2 (ja) 2022-07-08
EP4385571A3 (en) 2024-08-28
KR102615565B1 (ko) 2023-12-18
US20190192495A1 (en) 2019-06-27
IL265232A (en) 2019-05-30
CA3036062A1 (en) 2018-03-15
EP3509594A1 (en) 2019-07-17
EP3509594A4 (en) 2020-05-06
WO2018048942A1 (en) 2018-03-15
CN109922803A (zh) 2019-06-21
EP4385571B1 (en) 2026-05-06
CN117180280A (zh) 2023-12-08
BR112019004513A2 (pt) 2019-06-18
EP3509594C0 (en) 2025-02-26
CN109922803B (zh) 2023-09-22
EP4385571A2 (en) 2024-06-19
MX2019002612A (es) 2019-08-21
JP2019526589A (ja) 2019-09-19
AU2017324444A1 (en) 2019-04-11
MA46203A (fr) 2019-07-17
EP4052707A1 (en) 2022-09-07
KR20230162996A (ko) 2023-11-29
KR20190065265A (ko) 2019-06-11

Similar Documents

Publication Publication Date Title
EP4385571B1 (en) A lysyl oxidase-like 2 inhibitor for use in treating primary myelofibrosis
ES2915851T3 (es) Péptidos quiméricos de FGF19 para usar en el tratamiento de trastornos de ácidos biliares
US9421208B2 (en) Methods for the treatment of solid tumors
ES2753264T3 (es) Modelos de cáncer y métodos asociados
JP2017526713A (ja) 線維症を処置するためのセニクリビロック併用療法
CN105338977A (zh) 艾日布林和乐伐替尼作为治疗癌症的联合疗法的用途
BR112020016500A2 (pt) Agente preventivo ou terapêutico e composição farmacêutica para doença inflamatória ou doença óssea
BR112021001233A2 (pt) método para tratar câncer em um paciente, uso de uma quantidade terapeuticamente eficaz de gdc-0077 e quantidade terapeuticamente eficaz de gdc-0077
US20190282541A1 (en) Use of eribulin and histone deacetylase inhibitors in the treatment of cancer
JP7749542B2 (ja) 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート
US20040192621A1 (en) Anti-tumor agent
US20220079895A1 (en) Composition for preventing or treating liver diseases
JP2016520665A (ja) Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
CA3005961C (en) An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
WO2014087240A2 (en) Compositions, methods and kits for preventing, reducing, and eliminating cancer metastasis
JP2019019146A (ja) 腎臓病及び他の疾患の治療方法
ES2777501T3 (es) Terapia de anticuerpos ANTI-VEGFR2 para carcinoma hepatocelular
KR102684334B1 (ko) 지방간염, 지방증 또는 섬유증의 예방 또는 치료용 복합 제제
CN113874029B (zh) 基于cp2c靶向肽的抗癌剂
JP2025505187A (ja) 体重減少の方法および骨格筋量を保存する方法
US20220409582A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
CN114401745A (zh) 包含fxr激动剂的治疗
US20260014194A1 (en) Combinations comprising metap2 inhibitors for the treatment of cancer
ES2715556T3 (es) Terapia combinada con roneparstat del mieloma múltiple
TW202519221A (zh) Ｗｅｅ１抑制劑及ｐｋｍｙｔ１抑制劑之組合